Research programme: phosphodiesterase inhibitors - ICOS
Alternative Names: PDE inhibitors research programme ICOS; Phosphodiesterase inhibitors research programme - ICOSLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator ICOS Corporation
- Class
- Mechanism of Action Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease; Urinary incontinence
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Urinary-incontinence in USA
- 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly